Bayer AG develops, manufactures and markets pharmaceuticals, healthcare products, agricultural products and specialty materials worldwide. The Pharmaceuticals segment offers prescription pharmaceuticals for the treatment of hypertension, cardiovascular and infectious diseases, cancer, multiple sclerosis, and contraception. The Consumer Health segment offers over-the-counter drugs, dermatologicals, human and animal nutritional supplements, veterinary drugs, and animal care products; glucometers; and injection systems, and contrast agents for diagnostic procedures. The Crop Protection segment of the company supplies herbicides, fungicides, insecticides and seed treatment products; products for the horticultural and greenhouse industries; and non-agricultural pest and weed control products. The MaterialScience segment offers materials in the fields of polyurethanes and polycarbonates; coatings and adhesive raw materials primarily for the protection of automobiles, aircraft and wind turbines; functional films; and inorganic base chemicals such as chlorine, sodium hydroxide solution, hydrogen, hydrochloric acid, and nitric acid. The company enters into a strategic alliance with OncoMed Pharmaceuticals, Inc. research, development and sales of therapeutic agents for the control of cancer stem cells; and with the German Cancer Research Center for the development of drug treatments for cancer. Bayer AG was founded in 1863 and is based in Leverkusen, Germany.
How to buy Bayer AG shares?
We will help you buy Bayer AG shares and advise you on all matters related to the company's financial information.
Will sell the veterinary business and the over-the-counter lines of Copperstone sunscreens and Dr. Scholl's foot care products. The decision is connected with the desire to regain the confidence of investors, irritated by a series of failures and a serious drop in stock prices of the German chemical-pharmaceutical giant. The inventor of aspirin faced massive challenges, from declining demand for consumer goods to the instability of the prescription drug trade.
The share price of Bayer is in a protracted fall. Image: Yahoo! finance.
For example, the consumer business of Bayer, which received serious nourishment in 2014 thanks to the acquisition Merck & Co.'s $14.2 billion cash division experienced a drop in sales in the United States as people shopped more online than at traditional pharmacies for additional discounts. Over the first nine months of 2018, OTC sales fell 7.7%, while in 2017 it lost 2.9%. For example, demand for Copperstone, the antifungal Canesten, the analgesic, antipyretic, and anti-inflammatory Alka-Seltzer, and the antiallergic Claritin (Loratadine) have already declined by 15.2%; 12.4%; 11.7% and 11.0% this year.
Image: Alan Diaz/AP. The sale of the Copperstone and Doctor Shoals lines will be worth approximately 1 billion euros ($1.14 billion).
The veterinary business generated €1.57 billion ($1.77 billion) in 2017, up 3.2% from 2016. However, its contribution to the total income of the Bayer group is very insignificant - 4.5%. Bayer currently ranks fifth in the animal medicine market, behind Zoetis as a stand-alone part of Pfizer, Elanco as a stand-alone company, Eli Lilly, private German Boehringer Ingelheim and the aforementioned Merck & Co. To scale it against the backdrop of strengthening competitors, additional funds are needed, which are not currently available.
Bayer's veterinary business is in need of fresh blood as growth is falling. Image: Bloomberg. The value of this business is estimated 6-7 billion euros (6.8-7.9 billion dollars).
Acquisition of Monsanto, the world's leading supplier of genetically modified seeds and herbicides, completed in June 2018, at $63 billion. Not only has this plunged the company into heavy debt (by the end of this year, net debt will approach 37 billion euros), now it has to deal with with nearly 10,000 lawsuits alleging Roundup herbicide causes cancer.
In August 2018, a San Francisco court ruled the determination that the non-selective systemic herbicide glyphosate contained in Roundup, which is used to control weeds and which is the world's largest herbicide, is a carcinogen that increases the risk of developing non-Hodgkin's lymphoma in workers. The court ruled to pay 289 million dollars to the gardener who suffered from the "Roundup".
Image: Benoit Tessier/Reuters. It is appropriate to recall that in the run-up to the Monsanto purchase, industry experts feared the possible disruption of Bayer's pharmaceutical business. The latter defended the chosen strategy, the presence of clear potentials for the development of the drug portfolio. From 2020, the German corporation will begin to face a gradual loss of patent protection protecting a couple of its most profitable prescription drugs - the anticoagulant Xarelto (Xarelto, rivaroxaban) and the ophthalmic Eylea (Eylea, aflibercept).
Bayer prescription drug patent expiration dates. Prescription drugs continue to be Bayer's main moneymaker, generating 16.85 billion euros ($19.15 billion) in 2017, accounting for 48% of total revenue of 35 billion euros ($39.8 billion) . Investments in third-party research partners will be increased, but the idea of friendship with those developers of molecules that are close to being ready to enter the market will not be forgotten. But all this is very expensive: for example, in November 2017, a deal with Loxo Oncology for oral selective tropomyosin receptor kinase (Trk) inhibitors, including larotrectinib, stood at $ 1.55 billion in royalties . Be that as it may, Bayer will continue to expand its expertise in such interesting areas as hemophilia and hematology, cardiology, women's health, and oncology.
The layoffs, which will affect 10% of Bayer's 118,200 employees and will be completed by the end of 2021, are distributed as follows: half of the employees planned for layoffs are employed in corporate, support and commercial structures, a third will lose their jobs in the agricultural business due to the integration of Monsanto, 1250 positions will be affected by the pharmaceutical department, another 1100 people will leave the over-the-counter division.
Bayer forecasts that staff cuts will result in annual savings of 2.6 billion euros ($2.96 billion) starting in 2022. This amount includes cash resources received due to synergies from the acquisition of Monsanto. However, preliminary it will be necessary to spend somewhere around 4.4 billion euros (5 billion dollars) at a time on the costs associated with staff reductions. The cost savings will also help free up funds for a planned €35bn ($39.8bn) investment that the company expects to invest in development through the end of 2022. More than two-thirds of this budget is allocated to research and development.
Society, 20 Mar, 06:06
U.S. jury finds weed killer causes cancer ... the jury concluded that the German company's Roundup Bayer causes cancer. The fault of the company and the amount of damage caused yet... for the company's Roundup weed control Bayer contributes to the appearance of cancer in humans, reports Reuters. Bayer acquired the manufacturer of the product, Monsanto, in 2018 ... . Glyphosate is used in most herbicides, and Monsanto, which she purchased Bayer, was not protected by a patent, the agency notes. Also, in April... Bayer withdraws lawsuit against the FAS in connection with the merger with Monsanto ... this was reported to RBC by the head of the public relations department of the FAS Irina Kashunina. " Bayer withdrew his claim,” she said. In September 2016, the FAS company called the transfer of breeding technologies a condition of its approval of the deal Bayer Russian agrarians and making Russian companies access to databases... services illegal. At the end of April, the FAS approved the merger Bayer and Monsanto. The German company agreed to comply with the order of the Russian antimonopoly authority... FAS approved a deal to create the world's largest producer of GMOs ... the world's largest producer of GMOs as a result of the merger of the German Bayer and American Monsanto. Bayer will transfer seed breeding and digital technologies to Russian farmers ... the prescription is valid for five years, the report says Bayer. As directed by the FAS, Bayer will transfer individual molecular breeding aids for a number of crops, such as...Business, 21 Mar 2018, 15:32
European Commission approves Bayer purchase of Monsanto for $66 billion The European Commission (EC) has approved a deal to buy a German pharmaceutical company Bayer AG of US herbicide manufacturer Monsanto. This was reported by the press service of... The Federal Antimonopoly Service (FAS) of Russia has set a condition for its approval of the transaction Bayer and Monsanto transfer of breeding technologies from a German company to Russian farmers and...Business, 14 Feb 2018, 19:52
Court in Moscow accepts Bayer's lawsuit against FAS The Moscow Arbitration accepted the claim Bayer to the Federal Antimonopoly Service of Russia. This follows from the materials of the court. ... . The lawsuit filed by the German company against the FAS became known on February 13. Bayer dissatisfied with the department’s refusal to approve its merger deal with the American... Bayer Russian farmers and providing Russian companies with access to databases... Bayer Bayer Bayer FAS intervenes in a deal to create the world's largest producer of GMOs ... a takeover deal by a German chemical-pharmaceutical company Bayer herbicide manufacturer Monsanto only on the condition that Bayer will transfer technologies to Russian farmers, they say ... competition in the markets for seeds and digital farming FAS wants to oblige Bayer transfer, on the basis of a non-exclusive license, breeding technologies necessary ...Business, 14 Sep 2016, 15:29
Bayer Bayer Bayer BayerBusiness, 14 Sep 2016, 15:29
Bayer closes record deal in German business history ...Bloomberg. Monsanto purchase announcement posted on website Bayer. The deal has been approved by the boards of both companies. Bayer will buy back Monsanto shares at a price of $128 per..., Bloomberg notes. The deal is yet to be approved by antitrust regulators. In the message Bayer it is noted that she will pay Monsanto $ 2 billion if permission is given to ... in Vietnam to destroy the jungle in which the guerrillas were hiding. Concern Bayer was founded in 1863 as a drug manufacturer. In 1896...Business, 06 Sep 2016, 06:11
Bayer Bayer BayerBusiness, 06 Sep 2016, 06:11
Bayer says it's willing to pay $127.50 per Monsanto share ... published on the official website of the German concern. As noted in the statement, Bayer is ready to raise the price of the securities of an American company on the condition ... the world's producer of seeds and pesticides. In July, Monsanto rejected the offer. Bayer about the $65 billion purchase and called it "financially inadequate... on top of the $62 billion already agreed upon." Bayer will likely drop the Monsanto name after the takeover. Thus in... Bayer Bayer Bayer Bayer Media learned about Bayer's intention to raise $40 billion to buy Monsanto Bayer AG intends to raise another $40 billion to buy Monsanto, and... half a dozen banks. Interlocutors of the agency note that the amount that it plans to borrow Bayer, may still change. They explained that this will happen in that ... more funds will be needed to buy Monsanto. Representative Bayer declined to comment. May, 23rd Bayer announced that it is ready to acquire Monsanto based on ... Bayer Bayer Media learned of Monsanto's rejection of Bayer's $62 billion offer ... company management believes shareholders deserve a better offer. On Monday Bayer said it was ready to acquire Monsanto for $122 per share... upon request for comment from representatives of both companies. Main specialization Bayer is the production of chemical and pharmacological products. According to the company's annual report... Bayer Bayer Bayer Bayer offered to buy US Monsanto for $62 billion ... information about a possible deal has not yet been leaked to the media. CEO Bayer Werner Baumann told reporters that the company expects soon ... Monsanto, the agency notes. According to Bloomberg sources familiar with the situation, Bayer will likely drop the Monsanto name after the takeover. Thus in Bayer want to distance themselves from Monsanto's reputation, which is often criticized for... ... stores more domestic products. . VTsIOM and international concern Bayer Bayer Barometer", the purpose of which was to study key aspects of the quality of life ... employers themselves are ready for the agro-industrial complex. For example, the head of the marketing department Bayer28 Sep 2015, 14:37
More than half of Krasnodar residents report a shortage of Russian products ... on the shelves of stores more domestic products.. VTsIOM and the international concern Bayer conducted a joint study Bayer Barometer", the purpose of which was to study the key aspects of quality ... employers themselves are ready for the agro-industrial complex. For example, the head of the marketing department Bayer CropScience Viktor Borisenko said that the company is actively cooperating with universities... Bayer Bayer Bayer Bayer will produce drugs at the St. Petersburg pharmaceutical plant ... » Alexander Borisov. According to Borisov, within the framework of a 10-year contract Bayer will invest in the modernization of Polisan's production lines. Release of Magnevist, Gadovist and Ultravist... in 2014, not a single package of a localized drug Bayer was not sold in Russia. "Medsintez" and Bayer remain strategic partners, first commercial batch... The largest pharmaceutical concern earned 1.5 billion euros ... .Bayer- the world's largest chemical and pharmaceutical concern, which includes three subgroups ( Bayer Material Science, Bayer CropScience and Bayer HealthCare) and three service companies ( Bayer business service, Bayer Technology Service and Currenta). Concern Bayer produces about 5...Economics, 26 Feb 2010, 09:58
Bayer profit in 2009 fell more than expected ... the last quarter did not allow the company to meet the consensus forecast: net income Bayer Group according to the results of the IV quarter of 2009. increased by only 44 ... 798 million euros, then in 2009. Bayer spent another 766 million euros. In 2010 chapter Bayer Werner Wenning expects growth as sales... -The company's headquarters is located in Leverkusen (Germany). Main activities Bayer- health care, plant protection and production of high-tech materials. The company has a staff... Potency pills worth $5 million stolen in Germany ... that increase male potency. . As the representatives of the company said last Monday Bayer AG, over a month ago, a masked gang of four... Bayer AG's net profit rises to 4.64 billion euros Net profit of the German pharmaceutical concern Bayer AG for 9 months of 2007 grew by 3.4 times - ... according to the company's financial report published on Tuesday, sales Bayer for 9 months of this year increased by 16% and amounted to ... 2006, recorded at the level of 2.56 billion euros. Net profit Bayer according to the results of the III quarter of this year. rose to 3.7 ... Bayer sells HC Starck division for €1.2bn ... published today by a German company. . Under the terms of the deal, investors will pay Bayer 700 million euros in cash and will assume... is used to finance the acquisition of Schering. In particular, it will allow Bayer reduce net debt by 1 billion dollars and make a profit ... carry out an IPO within the next 3-5 years. Net profit Bayer in the second quarter of 2006 increased by 11.3% - up to 452 ... Merck sells its stake in Schering to Bayer ... a share - 1 euro more than was originally willing to pay Bayer. . Thus, the confrontation between the two leaders of the pharmaceutical industry in Germany ended ... from the struggle back in April of this year, after Bayer offered holders of Schering, the largest manufacturer of contraceptives, 86 euros for ... acquisitions of shares in Schering demanding that Merck be banned from voting. Bayer also expressed its readiness to increase the amount of the offer to purchase, without specifying ... EU regulators clear Bayer to buy Schering ... European Union regulators have approved a deal to acquire a German pharmaceutical group Bayer AG of Schering AG, the world's largest pharmaceutical manufacturer... does not violate European antitrust laws. . Shortly after the announcement of the European Commission, the leadership Bayer asked Schering shareholders to approve the deal by 31 ... . On March 27, Schering's Supervisory Board approved the proposal Bayer AG on the purchase of the company.Formerly Bayer AG announced the issue of Eurobonds in the amount of 2 ... Bayer AG offered $20 billion for Schering ... maturing in June 2009 will be issued by the company Bayer Capital Corporation B.V. Eurobonds are subject to mandatory conversion into new shares Bayer AG. The bonds are of a subordinated nature and are secured by subordinated guarantees from A ship with 1.8 tons of nitric acid sank in the Rhine ... Reine .. The cause of the fire was an incident in a dock owned by a chemical concern Bayer AG in the port of Krefeld. As a result of a pipeline rupture,... Bayer unit could be acquired for $15 billion ... has already negotiated with the investment bankers of the German concern Bayer. Pharmaceutical sales volumes Bayer amount to $8.2 billion, while... . GlaxoSmithKline is one of the top three pharmaceutical groups in the world and the acquisition Bayer could be the first major deal the company has made since... last year. Recall that the pharmaceutical division of the concern is in a difficult situation. Bayer set its own information policy in connection with the drug scandal...Maximum leverage
- MetaTrader4 & MetaTrader5: 1:20 (5% margin)
- On NetTradeX, equity CFD leverage equals trading account leverage (maximum 1:20)
8 stock exchanges, 400+ share CFDs
- We offer over 400 stock CFDs from 8 of the world's leading stock exchanges.
Commission
- From 0.1% of the transaction volume, but for US shares - $0.02 per share, for Canadian shares - 0.03 CAD per share. The commission is charged when opening and closing a position. When opening and closing a trading position, a commission is charged from the account. For transactions with US shares (instruments named "#S-...") the fee is $0.02 per share, and for transactions with Canadian shares ('#CA-…') it is 0.03 CAD per share. For transactions with other shares, the commission is from 0.1% of the transaction volume.">
- For NetTradeX and MT4, the minimum transaction fee is 1 of the quote currency, except for Chinese stocks with a min. com. 8 HKD, Japanese shares - 100 JPY and Canadian shares - 1.5 CAD. For MT5, the minimum commission is determined by the currency of the account balance - 1 USD/1EUR/100 JPY (only 1 USD for US stocks).
CFD Dividend Adjustment per Share = Dividend Per Share
- Holders of long (buy) CFD positions receive a dividend adjustment equal to the dividend payment. If a long position is opened on the instrument at the opening of trading on the day of the adjustment payment (coincides with the ex-dividend date), then a dividend adjustment is credited to the client's account. In contrast, if a short position is opened, the dividend adjustment is deducted from the client's account.
Imagine that Alcoa Inc. declared a quarterly dividend in the amount of $0.03, the date of calculation of the dividend adjustment is 08.05.2014.If a trader had a long position of 1000 shares on the #S-AA instrument before the beginning of the American trading session on May 08, 2014, then the amount of $30.00 ($0.03*1000) will be credited to his account.
If a trader had a short position, then $30.00 would be deducted from his account.
Dividends can be accrued in the form of share shares, as well as in a mixed form - a part in share shares plus a part in currency.At the same time, dividends in shares are converted into currency at the current share price.
From the accrued positive dividend adjustment, it is possible to withhold tax, as well as commission for the operation of accruing/writing off the adjustment.
"> - Detailed information on page "
Bayer AG has released its 2017 financials.
The company's total sales increased by 0.2% to 35 billion euros against the background of the growth of the main segment - pharmaceuticals - by 2.6% to 16.8 billion euros. by expanding sales both in the US and in other countries. Growth drivers were Harelto drugs +12.6% (treatment of cardiovascular diseases, prevention of thrombosis); Eylea +15.7% (treatment of eye diseases); Xofigo + 23.3% (cancer treatment); Stivarga +14.5% (cancer treatment); Adempas +16.1% (treatment of cardiovascular diseases).
The segment of over-the-counter drugs showed a decrease in sales by 2.9% to 5.9 billion euros. At the same time, it should be noted that the division recorded good growth in Europe, the Middle East, Africa, and especially in Germany. Sales in North and Latin America, as well as in the Asia-Pacific region, slowed down significantly. The drop in sales in the latter region was due to a change in the legal status of two skin care drug brands (transition from over-the-counter drugs (OTC) to prescription drugs) by the Chinese authorities, which led to a decrease in sales of 70 million euros in the fourth quarter of 2017 alone. of the year. The largest revenue growth in this segment was shown by such products as: Elevit +3.8% (vitamin product for pregnant women) and Bepanthen +4.7% (skin care).
Revenues in the area of protection of agricultural products decreased by 3.4%, amounting to 9.6 billion euros. This drop was mainly driven by a 22.5% decline in sales in Latin America to 1.9 billion euros due to adverse weather conditions, a weak economy and high stocks of these products, especially in Brazil. At the same time, we note the continued expansion of business in North America (revenue by 6% to 2.8 billion euros), which partially offset the decline in Latin America.
The Animal Health business, which operates as a separate business unit, posted a 3.2% increase in sales to 1.6 billion euros. The highest demand was observed in North America (+5.5%) and the Asia-Pacific region (+5.7%).
The holding's total revenue in geographic terms showed the highest sales growth in the Asia-Pacific region by 3% to 7.6 billion euros; The North American market grew by 0.8% to 10.1 billion euros; The European market together with the Middle East and Africa showed growth by 2.5% to 13.4 billion euros, while sales in Latin America decreased by 12.6% to 3.8 billion euros.
The company's operating profit increased by 2.9% to 5.9 billion euros. The growth in operating profit was supported by a decrease in operating costs to 29.1 billion euros (-0.3%).
Net financial expenses in the reporting period increased by 37.4% to 1.3 billion euros due to an increase in interest expenses.
As a result, the group's net income from continuing operations decreased by 13.5% to 3.2 billion euros. Income from discontinued operations in the reporting period amounted to 4.8 billion euros. Of this amount, €4.5 billion came from the deconsolidation of Covestro. Back in the third quarter of last year, Bayer sold part of its stake in Covestro, losing control. Note that Covestro is now classified as an associate and its results will be accounted for using the equity method, and in the current year - January 10, 2018 - Bayer AG further reduced its direct share in Covestro from 24.6% to 14.2%; in addition, 8.9% of the company's shares are owned by the Bayer Pension Trust. In the medium term, Bayer intends to sell Covestro outright.
Speaking about the future results of the company, it is impossible not to mention the merger of Bayer AG with Monsanto Company, a multinational company that occupies a leading position in the field of plant biotechnology. According to Bayer's management, the two companies complement each other perfectly in terms of product line, and the deal is expected to close in early 2018. For the purposes of the deal, Monsanto Company is valued at $66 billion, with Bayer already successfully syndicating the loan. At the moment it is equal to 49.7 billion dollars. The company intends to raise the rest by selling part of its current assets. This is evidenced by the sale of a stake in Covestro, as well as the already signed agreement on the sale of individual enterprises in the agricultural protection segment to the chemical group BASF for 5.9 billion euros.
After the release of financial statements, we slightly lowered our forecast of financial indicators, taking into account the retired segment. The fall in EPS, ROE and BV share next year is due to the lack of revenue from the discontinued operations of Covestro. In addition, the decrease in forecast indicators was affected by the lengthening of the time for regulators to consider the parameters of the Monsanto takeover transaction - the financial result of the American company in our Bayer model began to be taken into account from the second half of 2018.
Bayer AG is currently trading on a 2018 P/E of around 15 and a 2018 P/BV of around 2 and is one of our priorities.
___________________________________________
